SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense market volatility and high-volume trading as investors grapple with a massive short squeeze and concerns over potential share dilution through an at-the-market offering. The community remains deeply divided, with some traders betting on continued parabolic growth driven by institutional ownership, while others warn of an impending correction and significant risks for retail investors.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF is surging as the community reacts to reports that the administration is expected to move toward marijuana reclassification as early as Wednesday. Investors are closely tracking potential Schedule III developments, leading to intense discussion around sector-wide bullish sentiment, institutional inflows, and the impact of potential regulatory shifts on U.S. multi-state operators.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is driving intense community discussion following a new equity offering announcement, with investors debating whether the resulting share dilution is a strategic move to fund growth ahead of potential cannabis rescheduling or a recurring cycle of value destruction. While the stock faces immediate downward pressure and sharp criticism from vocal retail bears regarding management's leadership, others view the volatility as a setup for a technical breakout fueled by expectations of federal policy shifts.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

NMAX is currently seeing significant retail interest and volatility as traders discuss its potential as a short-squeeze candidate, with many drawing parallels to historical squeezes like CAR and GME. While supporters emphasize the stock's high short interest and upcoming earnings catalysts, critics remain focused on the company's financial performance and the aggressive retail sentiment surrounding the ticker.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is generating significant investor buzz as the company prepares to ramp up volume production of its more affordable R2 SUV, viewed by the community as a critical catalyst for future growth and profitability. The stock is currently a major focus for traders debating its long-term potential against competitors, with active discussions centering on institutional accumulation, a significant short interest squeeze narrative, and the company's strategic partnerships for AI-driven software and energy storage.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense bullish sentiment as it tests major resistance levels, driven by ongoing institutional inflows and excitement over crypto-focused ETFs. The community is actively debating the potential for a massive short squeeze as leverage builds, while participants remain hyper-focused on the asset's ability to maintain upward momentum amid broader geopolitical instability.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is in the spotlight following strong quarterly results that outperformed expectations, with investors closely watching the company's progress on production ramp-ups and 737 Max certification timelines. Community discussion is heavily divided between long-term optimism regarding a massive order backlog and defense contracts versus concerns over quality control, production delays, and persistent cash flow challenges.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending as investors cheer a multi-year partnership with Meta to develop custom AI silicon, which reinforces its dominant position in the AI infrastructure supply chain. The stock is seeing significant institutional attention as traders balance recent breakout momentum with heightened sensitivity to broader tech sector volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to management's confirmation of key commercial orders and a firm rebuttal of recent short-seller allegations. The community is actively discussing a potential short squeeze, citing high institutional interest and anticipation of further hyperscaler partnerships.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares is trending due to significant community frustration over a relentless, multi-week rally in the semiconductor sector that has triggered a prolonged losing streak for the fund. Investors are actively debating whether this represents a speculative bubble nearing a corrective phase or a structurally sound uptrend, with many participants struggling with the rapid decay and volatility inherent in holding a leveraged inverse instrument.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.</li><li>At 16 weeks, mobility improved significantly with eighty-one percent of patients achieving a clinically meaningful improvement, the company said.&nbsp;</li><li>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS.</li></ul>Shares of Kyverna Therapeutics, Inc. (KYTX) jumped 24% after hours on Tuesday after the company said that its experimental one-time CAR-T cell therapy delivered rapid, lasting improvements in mobility and reversed disability in patients with stiff person syndrome (SPS) in a trial.The results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.<h2 class="st-heading-2">Trial Results</h2>In the phase-2 trial, 26 patients who had not responded well to standard off-label therapies received a single dose of Kyverna’s miv-cel.At 16 weeks, mobility improved significantly; eighty-one percent of patients achieved a clinically meaningful improvement. Two-thirds of those who needed walking aids at the start no longer required them. All 26 patients were able to stop chronic immunotherapies entirely, the company said. Disability, muscle stiffness, and sensitivity to spasms also improved markedly, it added.Miv-cel was generally well-tolerated. The most common side effect was a temporary drop in neutrophil cell counts that was manageable, Kyverna said.<h2 class="st-heading-2">What Next?</h2>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS. If approved, it would become the first approved treatment for the condition and the first CAR-T therapy approved for any autoimmune disease.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around KYTX stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the company, highlighting the past experiences of its CEO Warner Biddle who previously worked with Kite Pharma. Kite was bought out by Gilead Sciences for $11.9 billion in 2017.<stembedurl>https://www.stocktwits.com/beststock/message/650960443</stembedurl>Another opined that miv-cel has a total addressable market of over $80 billion if its approved across multiple indications.<stembedurl>https://www.stocktwits.com/leon_dedrick/message/650960360</stembedurl><a href="https://stocktwits.com/symbol/KYTX">KYTX stock</a> has gained 11% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-gives-its-model-nemesis-lidar-vision-wallet-friendly-price-tag-unchanged/cZBIxJ6RI6N">NIO Gives Its Model Y Nemesis LiDAR Vision — Wallet-Friendly Price Tag Unchanged</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KYTX Stock Soars After Hours: What’s Driving The Rally? 

Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.

Equity

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer.</li><li>Legend is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed and marketed in collaboration with Johnson &amp; Johnson.</li></ul>Shares of Legend Biotech (LEGN) closed 18% higher on Monday, its best day since April 2023, following Eli Lilly and Company’s (LLY) buyout of its rival Kelonia Therapeutics for up to $7 billion.Lilly said earlier in the day that it has entered into a definitive agreement to acquire Kelonia to advance CAR-T cell therapies. Kelonia's lead program, KLN-1010, is an in vivo CAR-T therapy currently in early-stage studies for relapsed/refractory multiple myeloma.Under the terms of the deal, Lilly will pay Ketonia shareholders an upfront payment of $3.25 billion in addition to milestone payments. The transaction is expected to close in the second half of 2026.Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer. It is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson &amp; Johnson (JNJ).Last month, Legend said that more than 10,000 patients have been treated with Carvykti and that the franchise achieved profitability for the full year 2025. Carvykti net trade sales came in at $1.9 billion for the year.<h2 class="st-heading-2">Wall Street Takeaway</h2>Following the deal announcement, RBC Capital reportedly reiterated an ‘Outperform’ rating and $62.00 price target on Legend Biotech, opining that it highlights large pharma interest in the CAR-T market, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://m.in.investing.com/news/stock-market-news/rbc-capital-reiterates-legend-biotech-stock-rating-on-pharma-interest-93CH-5346810?ampMode=1">report</a> from Investing.com. Legend has potential sales of $2.8 billion in 2026, according to RBC.H.C. Wainwright also reiterated a ‘Buy’ rating with a $50 price target citing progress across the company’s CAR-T therapy programs, as <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/stock-market-news/hc-wainwright-reiterates-legend-biotech-stock-rating-on-pipeline-progress-93CH-5345904">per</a> Investing. First-in-human data from the LUCAR-G39D in vivo cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma is expected to start rolling in during the second half of 2026, with Wainwright flagging ASCO 2026 conference in late May to in early June as a plausible venue for the first readout.According to data from Koyfin, 14 of 16 analysts covering LEGN rate it ‘Buy’ or higher while two rate it ‘Hold.’ The 12-month average price target on the stock is $57.23, presenting a potential upside of about 128% from last close.<h2 class="st-heading-2"> How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LEGN stayed within the ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user sounded optimistic for Johnson &amp; Johnson acquiring Legend to “not split the revenue” with Carvykti.<stembedurl>https://www.stocktwits.com/Realtrader77/message/650805222</stembedurl>Another voiced optimism for the company getting bought out for $41/ per share, presenting significant upside.<stembedurl>https://www.stocktwits.com/Stockseeking/message/650804814</stembedurl><a href="https://stocktwits.com/symbol/LEGN">LEGN stock</a> has fallen 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jetblue-ceo-vows-strong-cash-pile-will-prevent-bankruptcy-in-2026-report/cZBdZIgRIzp">JetBlue CEO Vows Cash Pile Will Prevent Bankruptcy in 2026: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend. 

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

<ul class="summary-bullets"><li>The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.</li><li>An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, Anavex said.</li><li>This includes cognition, activities of daily life, and global clinical cognitive and functional outcome.</li></ul>Anavex Life Sciences Corp. (AVXL) on Monday reported new data about its Alzheimer’s drug blarcamesine, suggesting a slowdown in brain shrinkage.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III program, indicating that preservation of brain volume is linked to improved patient outcomes. The drug remains investigational and has not been approved by regulators.<a href="https://stocktwits.com/symbol/AVXL">Anavex shares</a> were up more than 13% in Monday’s opening trade.<h2 class="st-heading-2">What Does The Data Show?</h2>Anavex stated that the new data points to a reduction in brain volume loss over time. Brain shrinkage is a key marker of Alzheimer’s progression.“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR3 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Timo Grimmer, member of the Anavex Scientific Advisory Board.The company said that its trial data also shows that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, including cognition, activities of daily life, and global clinical cognitive and functional outcome.“The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine,” said Anavex CEO Christopher U. Missling.<h2 class="st-heading-2">What Does Anavex Do?</h2>Anavex is a New York-based biopharmaceutical that is involved in the development of therapeutics for the treatment of various disorders, including Alzheimer’s disease, Parkinson’s disease, and schizophrenia, among others.The company’s preclinical studies of blarcamesine showed that the oral drug candidate has the potential to halt or reverse the course of Alzheimer’s disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user said that Anavex’s brain volume preservation data is “incredibly exciting.”<stembedurl>https://stocktwits.com/Logic102/message/648270407</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is up 26% year-to-date, but down 54% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 23%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gold-price-recovers-as-trump-postpones-attack-on-iran-5-days-down-16-month/cZ3ma5TRI0O">Gold Price Recovers To $4,450 On Trump’s Iran Attack Pause – But Yellow Metal Is Still Down 15% In A Month After ‘Sell Everything’ Rout</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage

Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

<ul class="summary-bullets"><li>UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain.</li><li>The FDA recently said that data from uniQure’s Phase I/II trials were not sufficient and recommended a new randomized Phase III study.</li><li>RBC Capital estimates a 50% chance of eventual approval as Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130.</li></ul>Shares of uniQure N.V. (QURE) surged more than 20% on Monday, following upgrades from Wall Street firms, citing a potentially improving regulatory outlook for its Huntington’s disease therapy.Wells Fargo upgraded the company to ‘Overweight’ from ‘Equal Weight’ and sharply raised its price target to $60 from $15, according to The Fly. This implies a 243% potential rise from its current price of around $17.5.<h2 class="st-heading-2">Vinay Prasad’s Reported Departure In Spotlight</h2>Wells Fargo said the outlook for uniQure’s experimental gene therapy AMT-130 could improve following reports that Vinay Prasad will leave the U.S. Food and Drug Administration (FDA) next month. Prasad, who serves as both the Chief Medical and Scientific Officer and the Director of the Center for Biologics Evaluation and Research at the FDA, is set to leave next month, according to a Bloomberg report on Friday.Wells Fargo also noted that strong criticism from the media and the Huntington’s disease community over the FDA’s call for a new Phase 3 trial highlights stakeholder support for the therapy. That backing could strengthen the drug’s chances during review, approval, and commercialization.AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. It uses a virus to deliver genetic instructions that help lower the protein. The treatment is administered directly into the striatum, an area of the brain heavily affected by Huntington’s disease, through a surgical procedure.Separately, RBC Capital Markets upgraded uniQure to ‘Outperform’ from ‘Sector Perform’ and raised its price target to $35 from $11. The firm said Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130, estimating about a 50% chance of eventual approval.<h2 class="st-heading-2">FDA Seeks New Randomized Study</h2>The upgrades come after regulatory uncertainty weighed on the company earlier this year. The FDA recently said that data from uniQure’s Phase I/II trials were insufficient to support a marketing application and recommended that the company conduct a new randomized Phase III study, including a controversial sham surgery control group.uniQure has raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit. The company plans to request another meeting with the FDA in the second quarter of 2026 to discuss potential study designs.Despite the regulatory debate, AMT-130 has shown promising early data. In an earlier study, patients receiving a high dose of the gene therapy experienced about a 75% slower rate of disease progression after three years, along with a slower decline in both motor function and cognitive ability.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp rally, retail sentiment for <a href="https://stocktwits.com/symbol/QURE">QURE</a> on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to surge to $150 if the company receives the FDA approval.<stembedurl>https://stocktwits.com/ChineseTakeeout/message/646975511</stembedurl>Another user weighed the options present for short sellers and long-term investors.<stembedurl>https://stocktwits.com/sepsis74/message/646972082</stembedurl>The stock has declined nearly 28% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/saudi-arabia-begins-slashing-oil-production-tpet-batl-indo-shares-continue-to-draw-retail-buzz/cZdVlsWRIIj">Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Stocks Continue To Draw Retail Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF